Granahan Investment Management’s Xenon Pharmaceuticals XENE Stock Holding History

Granahan Investment Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.81M	Buy	129,443 +24,965	+24%	+$1.39M	0.28%	85
2026 Q1	$6.08M	Buy	104,478 +11,700	+13%	+$539K	0.29%	89
2025 Q4	$4.16M	Buy	92,778 +5,308	+6%	+$223K	0.18%	120
2025 Q3	$3.51M	Sell	87,470 -152,568	-64%	-$5.37M	0.14%	115
2025 Q2	$7.51M	Buy	240,038 +56,230	+31%	+$1.83M	0.31%	81
2025 Q1	$6.17M	Buy	183,808 +1,475	+0.8%	+$56K	0.31%	86
2024 Q4	$7.15M	Sell	182,333 -18,544	-9%	-$767K	0.3%	86
2024 Q3	$7.91M	Sell	200,877 -25,289	-11%	-$1.02M	0.31%	97
2024 Q2	$8.82M	Sell	226,166 -17,914	-7%	-$716K	0.35%	87
2024 Q1	$10.5M	Sell	244,080 -58,501	-19%	-$2.69M	0.37%	81
2023 Q4	$13.9M	Buy	302,581 +66,291	+28%	+$2.34M	0.46%	70
2023 Q3	$8.07M	Sell	236,290 -463	-0.2%	-$17.3K	0.29%	100
2023 Q2	$9.11M	Sell	236,753 -39,259	-14%	-$1.56M	0.28%	95
2023 Q1	$9.88M	Sell	276,012 -48,238	-15%	-$1.78M	0.3%	91
2022 Q4	$12.8M	Buy	324,250 +24,395	+8%	+$888K	0.39%	72
2022 Q3	$10.8M	Buy	299,855 +15,083	+5%	+$542K	0.35%	86
2022 Q2	$8.66M	Buy	284,772 +22,067	+8%	+$667K	0.3%	89
2022 Q1	$8.03M	Buy	262,705 +45,404	+21%	+$1.36M	0.2%	105
2021 Q4	$6.79M	Buy	217,301 +133,447	+159%	+$3.99M	0.14%	134
2021 Q3	$1.28M	Buy	83,854 +605	+0.7%	+$10.5K	0.02%	184
2021 Q2	$1.55M	Buy	83,249 +161	+0.2%	+$2.97K	0.03%	182
2021 Q1	$1.49M	Sell	83,088 -70,233	-46%	-$1.19M	0.03%	177
2020 Q4	$2.36M	Sell	153,321 -5,383	-3%	-$63K	0.05%	171
2020 Q3	$1.76M	Buy	158,704 +47,705	+43%	+$561K	0.06%	160
2020 Q2	$1.39M	Hold	110,999	–	–	0.05%	161
2020 Q1	$1.26M	Buy	110,999 +4,160	+4%	+$59.2K	0.07%	156
2019 Q4	$1.4M	Buy	106,839 +380	+0.4%	+$4K	0.06%	150
2019 Q3	$959K	Buy	106,459 +8,200	+8%	+$77.5K	0.05%	156
2019 Q2	$969K	Sell	98,259 -10,420	-10%	-$99.7K	0.05%	164
2019 Q1	$1.1M	Buy	+108,679	New	+$921K	0.06%	169

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Granahan Investment Management's XENE Position: Q2 2026 in Review

Granahan Investment Management increased its Xenon Pharmaceuticals (XENE) stake by 24% in Q2 2026, buying an estimated $1.39M and bringing the position to 129,443 shares worth $7.81M. The position accounts for 0.28% of the portfolio, ranked #85.

Granahan Investment Management first reported a position in XENE in Q1 2019 and has held it in 30 quarters since. The position peaked at $13.9M in Q4 2023. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Granahan Investment Management held 129,443 shares of Xenon Pharmaceuticals worth $7.81M as of Q2 2026.
Granahan Investment Management bought 24,965 Xenon Pharmaceuticals shares in Q2 2026, an estimated $1.39M.
Xenon Pharmaceuticals made up 0.28% of Granahan Investment Management's portfolio in Q2 2026, its #85 holding.
Granahan Investment Management first reported a position in Xenon Pharmaceuticals in Q1 2019 and has held it in 30 quarters since.
Granahan Investment Management's Xenon Pharmaceuticals position peaked at $13.9M in Q4 2023.
316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Granahan Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.